<?xml version='1.0' encoding='iso-8859-1'?>
<PASBIO>
    <framesest>
        <predicate lemma="proliferate">
            <roleset id="proliferate.01" name="" wordnet="1">
                <roles>
                    <role n="0" descr="thing becoming abundant&#09;&#09;&#09;&#09;// gene products //&#10;" />
                    <role n="1" descr="situation of becoming abundant&#10;" />
                    <role n="2" descr="location referring to organ, vitro&#10;" />
                </roles>
                <example src="EGRAM" no="0">
					<text>adult T cells, which are at rest under normal conditions, are able to proliferate strongly when transferred to lymphonic hosts.</text>
					<arg n="0">adult T cells</arg>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="0">
					<text>adult naive T cells, which are at rest under normal conditions, are able to proliferate strongly when transferred to lymphopenic hosts.</text>
					<arg n="0">adult naive T cells</arg>
					<arg n="1">when transferred to lymphopenic hosts</arg>
				</example>
				<example src="EGRAM" no="1">
					<text>adult naive T cells, which are at rest under normal conditions, are able to proliferate when transferred to lymphopenic hosts.</text>
					<arg n="0">adult naive T cells</arg>
					<arg n="1">when transferred to lymphopenic hosts</arg>
				</example>
				<example src="EGRAM" no="1">
					<text>ingenue T cells of adults, which are at rest under normal conditions, are able to proliferate when transferred to lymphonic hosts.</text>
					<arg n="0">ingenue T cells of adults</arg>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="2">
					<text>adult T cells, which are at rest under normal conditions, are observed to strongly proliferate when transferred to lymphonic hosts.</text>
					<arg n="0">adult T cells</arg>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="2">
					<text>Adult T cells, which are at rest in normal conditions, are proliferate as proliferative cells transferred to lymphonic hosts.</text>
					<arg n="1">transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="3">
					<text>adult T cells, which are at rest in normal conditions, are observed to proliferate when transferred to lymphonic hosts.</text>
					<arg n="0">adult T cells</arg>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="3">
					<text>Adult T cells, which are at rest under normal conditions, are proliferate for the proliferation of when transferred to lymphonic hosts.</text>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="4">
					<text>Adult T cells at rest, under normal conditions, may proliferate strongly when transferred to lymphocytic hosts.</text>
					<arg n="1">when transferred to lymphocytic hosts</arg>
				</example>
				<example src="EGRAM" no="4">
					<text>Adult T cells, which are at rest under normal conditions, can strongly proliferate when transferred to lymphonic hosts.</text>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="5">
					<text>adult T cells, which are at rest under normal conditions, can proliferate when transferred to lymphonic hosts.</text>
					<arg n="0">adult T cells</arg>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="5">
					<text>ingenue T cells of adults, which are at rest under normal conditions, can proliferate when transferred to lymphonic hosts.</text>
					<arg n="0">ingenue T cells of adults</arg>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="6">
					<text>Adult T cells at rest, under normal conditions, may proliferate strongly when transferred to lymphocytic hosts.</text>
					<arg n="1">when transferred to lymphocytic hosts</arg>
				</example>
				<example src="EGRAM" no="6">
					<text>Adult T cells, which are at rest under normal conditions, can strongly proliferate when transferred to lymphonic hosts.</text>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="7">
					<text>Adult T cells at rest, under normal conditions, may proliferated a sharp proliferation of transferred to lymph nodes.</text>
					<arg n="1">transferred to lymph nodes</arg>
				</example>
				<example src="EGRAM" no="7">
					<text>Adult T cells, which are at rest under normal conditions, may have strongly proliferated when transferred to lymphonic hosts.</text>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="8">
					<text>Adult T cells at rest, under normal conditions, may have A1 proliferation (proliferated to lymph node hosts).</text>
				</example>
				<example src="EGRAM" no="8">
					<text>Adult T cells, which are at rest under normal conditions, may have proliferated when transferred to lymphonic hosts.</text>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="9">
					<text>Adult T cells at rest, under normal conditions, may proliferated a sharp proliferation of transferred to lymph nodes.</text>
					<arg n="1">transferred to lymph nodes</arg>
				</example>
				<example src="EGRAM" no="9">
					<text>Adult T cells, which are at rest under normal conditions, may have strongly proliferated when transferred to lymphonic hosts.</text>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="10">
					<text>Adult T cells at rest, under normal conditions, have proliferated when transferred to lymphocytic hosts.</text>
					<arg n="1">when transferred to lymphocytic hosts</arg>
				</example>
				<example src="EGRAM" no="10">
					<text>Adult T cells, which are at rest under normal conditions, have proliferated when transferred to lymphonic hosts.</text>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="11">
					<text>Adult T cells, which are at rest under normal conditions, have acute A1 proliferation (when proliferated to lymphonic hosts).</text>
				</example>
				<example src="EGRAM" no="11">
					<text>Adult T cells, which are at rest under normal conditions, have strongly proliferated when transferred to lymphonic hosts.</text>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="12">
					<text>Adult T cells, at rest under normal conditions, have the ability to proliferate strongly when transferred to lymph nodes.</text>
					<arg n="1">when transferred to lymph nodes</arg>
				</example>
				<example src="EGRAM" no="12">
					<text>Adult T cells, which are at rest in normal conditions, have the ability to proliferate strongly when transferred to lymphonic hosts.</text>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="13">
					<text>adult T cells, which are at rest in normal conditions, have the ability to proliferate when transferred to lymphonic hosts.</text>
					<arg n="0">adult T cells</arg>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="13">
					<text>A0, which is unique to adults, has the ability to proliferate when transferred to lymphonic hosts.</text>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="14">
					<text>Adult T cells at rest, under normal conditions, may proliferate strongly when transferred to lymphocytic hosts.</text>
					<arg n="1">when transferred to lymphocytic hosts</arg>
				</example>
				<example src="EGRAM" no="14">
					<text>Adult T cells, which are at rest under normal conditions, can strongly proliferate when transferred to lymphonic hosts.</text>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="15">
					<text>Adult T cells at rest, under normal conditions, may proliferate when transferred to lymphocytic hosts.</text>
					<arg n="1">when transferred to lymphocytic hosts</arg>
				</example>
				<example src="EGRAM" no="15">
					<text>Adult T cells, which are at rest under normal conditions, can proliferate when transferred to lymphonic hosts.</text>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="16">
					<text>Adult T cells at rest, under normal conditions, may proliferate strongly when transferred to lymphocytic hosts.</text>
					<arg n="1">when transferred to lymphocytic hosts</arg>
				</example>
				<example src="EGRAM" no="16">
					<text>Adult T cells, which are at rest under normal conditions, can strongly proliferate when transferred to lymphonic hosts.</text>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="17">
					<text>Adult T cells at rest, under normal conditions, may proliferated a sharp proliferation of transferred to lymph nodes.</text>
					<arg n="1">transferred to lymph nodes</arg>
				</example>
				<example src="EGRAM" no="17">
					<text>Adult T cells, which are at rest under normal conditions, may have strongly proliferated when transferred to lymphonic hosts.</text>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="18">
					<text>Adult T cells at rest, under normal conditions, may have A1 proliferation (proliferated to lymph node hosts).</text>
				</example>
				<example src="EGRAM" no="18">
					<text>Adult T cells, which are at rest under normal conditions, may have proliferated when transferred to lymphonic hosts.</text>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="19">
					<text>Adult T cells, which are at rest under normal conditions, may have acute A1 proliferation (when proliferated to lymphonic hosts).</text>
				</example>
				<example src="EGRAM" no="19">
					<text>Adult T cells, which are at rest under normal conditions, may have strongly proliferated when transferred to lymphonic hosts.</text>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="20">
					<text>ingenue T cells for adults, which proliferated at rest under normal conditions, strongly proliferate when transferred to lymphonic hosts.</text>
					<arg n="0">ingenue T cells for adults</arg>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="20">
					<text>ingenue T cells of adults, which proliferated at rest in normal conditions, strongly proliferate when transferred to lymphonic hosts.</text>
					<arg n="0">ingenue T cells of adults</arg>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="21">
					<text>adult T cells, which proliferated at rest under normal conditions, proliferate when transferred to lymphocytic hosts.</text>
					<arg n="0">adult T cells</arg>
					<arg n="1">when transferred to lymphocytic hosts</arg>
				</example>
				<example src="EGRAM" no="21">
					<text>ingenue T cells of adults, which proliferated at rest under normal conditions, proliferate when transferred to lymphonic hosts.</text>
					<arg n="0">ingenue T cells of adults</arg>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="22">
					<text>Adult T cells, at rest, under normal conditions, proliferate strongly a1 (when transferred to lymphocytic hosts).</text>
				</example>
				<example src="EGRAM" no="22">
					<text>Adult T cells, which are at rest under normal conditions, proliferate strongly a1 (when transferred to lymphonic hosts).</text>
				</example>
				<example src="EGRAM" no="23">
					<text>adult naive T cells, which are at rest under normal conditions, will proliferate when transferred to lymphopenic hosts.</text>
					<arg n="0">adult naive T cells</arg>
					<arg n="1">when transferred to lymphopenic hosts</arg>
				</example>
				<example src="EGRAM" no="23">
					<text>ingenue T cells of adults, which are at rest in normal conditions, will proliferate when transferred to lymphonic hosts.</text>
					<arg n="0">ingenue T cells of adults</arg>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="24">
					<text>Adult T cells, at rest, under normal conditions, proliferate strongly when transferred to lymphocytic hosts.</text>
					<arg n="1">when transferred to lymphocytic hosts</arg>
				</example>
				<example src="EGRAM" no="24">
					<text>Adult T cells, which are at rest under normal conditions, proliferate strongly when transferred to lymphonic hosts.</text>
					<arg n="1">when transferred to lymphonic hosts</arg>
				</example>
				<example src="EGRAM" no="25">
					<text>After androgen withdrawal and angiogen treatment, androgen prostate cancer cells is able to stop proliferating and suffering from apoptosis, proliferate tumour regression.</text>
					<arg n="0">androgen prostate cancer cells</arg>
				</example>
				<example src="EGRAM" no="25">
					<text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells responding to androgen is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
					<arg n="0">prostate cancer cells responding to androgen</arg>
				</example>
				<example src="EGRAM" no="26">
					<text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells responding to androgen ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
					<arg n="0">prostate cancer cells responding to androgen</arg>
				</example>
				<example src="EGRAM" no="26">
					<text>After androgen withdrawal and angiogen treatment, prostate cancer cells responding to androgen was proliferate to trigger apoptosis, causing tumor regression.</text>
					<arg n="0">prostate cancer cells responding to androgen</arg>
				</example>
				<example src="EGRAM" no="27">
					<text>After androgen withdrawal and anti-androgen treatment, androgenic responsive prostate cancer cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
					<arg n="0">androgenic responsive prostate cancer cells</arg>
				</example>
				<example src="EGRAM" no="27">
					<text>After androgen withdrawal and angiogen treatment, androgen prostate cancer cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
					<arg n="0">androgen prostate cancer cells</arg>
				</example>
				<example src="EGRAM" no="28">
					<text>After the withdrawal of androgen and the treatment of anthandrogen, it is observed that androgen's responsive prostate cancer cells stop proliferating and undergo apoptosis will proliferate tumor regression.</text>
					<arg n="0">androgen's responsive prostate cancer cells</arg>
				</example>
				<example src="EGRAM" no="28">
					<text>After the androgen has been withdrawn and angiogen treatment, prostate cancer cells responding to androgen will proliferate tumor regression.</text>
					<arg n="0">prostate cancer cells responding to androgen</arg>
				</example>
				<example src="EGRAM" no="29">
					<text>After androgen withdrawal and anti-androgen treatment, androgen-responsive prostate cancer cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
					<arg n="0">androgen-responsive prostate cancer cells</arg>
				</example>
				<example src="EGRAM" no="29">
					<text>After the withdrawal of androgen and the treatment of anthandrogen, the cancerous prostate cells that are resistant to androgen can stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
				</example>
				<example src="EGRAM" no="30">
					<text>After androgen withdrawal and antiandrogen treatment, androgen-responsive prostate cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
					<arg n="0">androgen-responsive prostate cancer cells</arg>
				</example>
				<example src="EGRAM" no="30">
					<text>After the withdrawal of androgen and the treatment of anthandrogen, the androgen-resistant cancer cells ceased to proliferate and suffered apoptosis, causing tumor regression.</text>
				</example>
				<example src="EGRAM" no="31">
					<text>After androgen withdrawal and angiogen treatment, androgen cancer cells responded to prostate disease, ceased proliferation and were submitted to proliferate, resulting in tumor regression.</text>
					<arg n="0">androgen cancer cells</arg>
				</example>
				<example src="EGRAM" no="31">
					<text>After the withdrawal of androgen and the treatment of anthandrogen, the androgen-resistant cancer cells ceased to proliferate and suffered apoptosis, causing tumor regression.</text>
				</example>
				<example src="EGRAM" no="32">
					<text>After the withdrawal of androgen and the treatment of anthandrogen, carcinogenic cells of the prostate that respond to the androgen stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
					<arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
				</example>
				<example src="EGRAM" no="32">
					<text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells responding to androgen ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
					<arg n="0">prostate cancer cells responding to androgen</arg>
				</example>
				<example src="EGRAM" no="33">
					<text>After androgen withdrawal and angiogen treatment, angiogen prostate cancer cells has the ability to stop proliferating and suffering apoptosis, proliferate tumor regression.</text>
					<arg n="0">angiogen prostate cancer cells</arg>
				</example>
				<example src="EGRAM" no="33">
					<text>After androgen withdrawal and anti-androgen treatment, androgen-responsive prostate cancer cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
					<arg n="0">androgen-responsive prostate cancer cells</arg>
				</example>
				<example src="EGRAM" no="34">
					<text>After androgen withdrawal and antiandrogen treatment, androgen-responsive prostate cancer cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
					<arg n="0">androgen-responsive prostate cancer cells</arg>
				</example>
				<example src="EGRAM" no="34">
					<text>After the withdrawal of androgen and the treatment of anthandrogen, the androgen-resistant cancer cells ceased to proliferate and suffered apoptosis, causing tumor regression.</text>
				</example>
				<example src="EGRAM" no="35">
					<text>After the androgen has been withdrawn and angiogen treatment, cancer cells of the androgen prostate which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
					<arg n="0">cancer cells of the androgen prostate</arg>
				</example>
				<example src="EGRAM" no="35">
					<text>After the withdrawal of androgen and the treatment of anthandrogen, the androgen-resistant cancer cells with the ability to halt proliferation and suffer apoptosis will proliferate tumor regression.</text>
				</example>
				<example src="EGRAM" no="36">
					<text>After the withdrawal of androgen and the treatment of anthandrogen, androgen-resistant cancer cells can stop proliferating and undergo apoptosis, proliferate tumor regression.</text>
				</example>
				<example src="EGRAM" no="36">
					<text>After androgen withdrawal and angiogen treatment, androgen tumour cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
					<arg n="0">androgen tumour cells</arg>
				</example>
				<example src="EGRAM" no="37">
					<text>After the androgen has been withdrawn and angiogen treatment, cancer cells of the androgen prostate that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
					<arg n="0">cancer cells of the androgen prostate</arg>
				</example>
				<example src="EGRAM" no="37">
					<text>After the androgens have been removed and the treatment of anthandrogen, prostate cancer cells (androgen response) that are able to halt proliferation and suffer apoptosis will proliferate tumor regression.</text>
				</example>
				<example src="EGRAM" no="38">
					<text>After the androgens have been removed and the treatment of anthandrogen, the prostate cancer cells (androgen response) that are observed stop proliferate and suffer from apoptosis will proliferate tumor regression.</text>
				</example>
				<example src="EGRAM" no="38">
					<text>After androgens have been removed and anti-androgen treatment, androgen-responsive prostate cancer cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
					<arg n="0">androgen-responsive prostate cancer cells</arg>
				</example>
				<example src="EGRAM" no="39">
					<text>After the androgen has been withdrawn and angiogen treatment, cancer cells of the androgen prostate which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
					<arg n="0">cancer cells of the androgen prostate</arg>
				</example>
				<example src="EGRAM" no="39">
					<text>After androgens have been removed and anti-androgen treatment, androgenic responsive prostate cancer cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
					<arg n="0">androgenic responsive prostate cancer cells</arg>
				</example>
				<example src="EGRAM" no="40">
					<text>After androgen withdrawal and angiogen treatment, cancer cells from the androgen prostate which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
					<arg n="0">cancer cells from the androgen prostate</arg>
				</example>
				<example src="EGRAM" no="40">
					<text>After androgen withdrawal and antiandrogen treatment, prostate cancer cells responding to androgen ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
					<arg n="0">prostate cancer cells responding to androgen</arg>
				</example>
				<example src="EGRAM" no="41">
					<text>After androgen withdrawal and angiogen treatment, allergen prostate cancer cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
					<arg n="0">allergen prostate cancer cells</arg>
				</example>
				<example src="EGRAM" no="41">
					<text>After the withdrawal of androgen and the treatment of anthandrogen, the cancerous prostate cells resistant to androgen ceased proliferation and subjected to proliferate caused tumor regression.</text>
				</example>
				<example src="EGRAM" no="42">
					<text>After the androgen has been withdrawn and angiogen treatment, cancer cells of the androgen prostate which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
					<arg n="0">cancer cells of the androgen prostate</arg>
				</example>
				<example src="EGRAM" no="42">
					<text>After androgen withdrawal and anti-androgen treatment, androgen-responsive prostate cancer cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
					<arg n="0">androgen-responsive prostate cancer cells</arg>
				</example>
				<example src="EGRAM" no="43">
					<text>After the androgen has been withdrawn and angiogen treatment, cancer cells of the androgen prostate which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
					<arg n="0">cancer cells of the androgen prostate</arg>
				</example>
				<example src="EGRAM" no="43">
					<text>After androgens have been removed and anti-androgen treatment, androgenic responsive prostate cancer cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
					<arg n="0">androgenic responsive prostate cancer cells</arg>
				</example>
				<example src="EGRAM" no="44">
					<text>After the androgen has been withdrawn and angiogen treatment, cancer cells of the androgen prostate which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
					<arg n="0">cancer cells of the androgen prostate</arg>
				</example>
				<example src="EGRAM" no="44">
					<text>After androgen withdrawal and anti-androgen treatment, androgen-responsive prostate cancer cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
					<arg n="0">androgen-responsive prostate cancer cells</arg>
				</example>
				<example src="EGRAM" no="45">
					<text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells responding to androgen will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
					<arg n="0">prostate cancer cells responding to androgen</arg>
				</example>
				<example src="EGRAM" no="45">
					<text>After androgen withdrawal and angiogen treatment, prostate cancer cells respond to androgen will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
					<arg n="0">prostate cancer cells respond to androgen</arg>
				</example>
				<example src="EGRAM" no="46">
					<text>Cancer cells are proliferate by a higher proliferation capacity or a lower capacity to suffer scheduled cell death.</text>
				</example>
				<example src="EGRAM" no="46">
					<text>Cancer cells are thought to be characterized by a greater ability to proliferate or a lesser ability to suffer programmed cell death.</text>
				</example>
				<example src="EGRAM" no="47">
					<text>Cancer cells are proliferate by a higher capacity for strong proliferation or a decrease in the capacity to suffer scheduled cell death.</text>
				</example>
				<example src="EGRAM" no="47">
					<text>Cancer cells are thought to be characterized by a greater ability to proliferate strongly or a decrease in the ability to suffer programmed cell death.</text>
				</example>
				<example src="EGRAM" no="48">
					<text>Cancer cells are proliferating by increased proliferation capacity or decreased capacity to suffer scheduled cell death.</text>
				</example>
				<example src="EGRAM" no="48">
					<text>Cancer cells are proliferating by increased proliferation capacity or decreased ability to suffer programmed cell death.</text>
				</example>
				<example src="EGRAM" no="49">
					<text>Cancer cells are proliferating by a higher capacity for strong proliferation or by a decrease in the capacity to suffer scheduled cell death.</text>
				</example>
				<example src="EGRAM" no="49">
					<text>Cancer cells are proliferating by a greater capacity for strong proliferation or a decrease in the ability to suffer programmed cell death.</text>
				</example>
				<example src="EGRAM" no="50">
					<text>Cancer cells may be proliferate by increased proliferation or scheduled cell death.</text>
				</example>
				<example src="EGRAM" no="50">
					<text>Cancer cells can be proliferate by greater proliferation or less programmed cell death.</text>
				</example>
				<example src="EGRAM" no="51">
					<text>Cancer cells may be proliferate by higher capacity for strong proliferation or lower capacity to suffer scheduled cell death.</text>
				</example>
				<example src="EGRAM" no="51">
					<text>Cancer cells can be characterized by greater ability to proliferate strongly or less ability to suffer programmed cell death.</text>
				</example>
				<example src="EGRAM" no="52">
					<text>A0 has been proliferate by a higher proliferation capacity or a reduced capacity to suffer scheduled cell death.</text>
				</example>
				<example src="EGRAM" no="52">
					<text>A0 has been characterized by a greater proliferating ability or a reduced ability to undergo programmed cell death.</text>
				</example>
				<example src="EGRAM" no="53">
					<text>cancer cells has been proliferate by a higher proliferation capacity or a decrease in the scheduled cell death capacity.</text>
					<arg n="0">cancer cells</arg>
				</example>
				<example src="EGRAM" no="53">
					<text>cancer cells has been characterized by a greater ability to proliferate strongly or a decrease in the ability to undergo programmed cell death.</text>
					<arg n="0">cancer cells</arg>
				</example>
				<example src="EGRAM" no="54">
					<text>Cancer cells may be proliferate by increased proliferation or scheduled cell death.</text>
				</example>
				<example src="EGRAM" no="54">
					<text>Cancer cells can be proliferate by greater proliferation or less programmed cell death.</text>
				</example>
				<example src="EGRAM" no="55">
					<text>Cancer cells may be proliferate by a higher capacity for strong proliferation or a lower capacity for programmed cell death.</text>
				</example>
				<example src="EGRAM" no="55">
					<text>Cancer cells can be characterized by a greater ability to proliferate strongly or a lower ability to undergo programmed cell death.</text>
				</example>
				<example src="EGRAM" no="56">
					<text>A0 is proliferate by greater proliferation capacity or reduced capacity to suffer scheduled cell death.</text>
				</example>
				<example src="EGRAM" no="56">
					<text>A0 is characterized by a greater proliferating ability or a reduced ability to suffer programmed cell death.</text>
				</example>
				<example src="EGRAM" no="57">
					<text>A0 is proliferate by a higher capacity for strong proliferation or decreased capacity to suffer scheduled cell death.</text>
				</example>
				<example src="EGRAM" no="57">
					<text>A0 is characterized by a greater ability to proliferate strongly or a decrease in the ability to suffer programmed cell death.</text>
				</example>
				<example src="EGRAM" no="58">
					<text>cancer cells is proliferating by increased proliferation or decreased capacity to suffer scheduled cell death.</text>
					<arg n="0">cancer cells</arg>
				</example>
				<example src="EGRAM" no="58">
					<text>cancer cells is proliferating by increased proliferation or decreased ability to suffer programmed cell death.</text>
					<arg n="0">cancer cells</arg>
				</example>
				<example src="EGRAM" no="59">
					<text>cancer cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
					<arg n="0">cancer cells</arg>
				</example>
				<example src="EGRAM" no="59">
					<text>cancer cells is proliferating by a greater capacity for strong proliferation or a decrease in the ability to suffer programmed cell death.</text>
					<arg n="0">cancer cells</arg>
				</example>
				<example src="EGRAM" no="60">
					<text>In addition, HD CD4+ T cells specific for HIV in viremic patients is able to proliferate in response to HIV antigens when costimulation was provided by anti-CD28 antibodies in vitro.</text>
					<arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
					<arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="60">
					<text>In addition, HD CD4+ T cells specific to HIV in viremics patients is able to proliferate in response to HIV A1 antigens (when costimulation was provided by anti-CD28 antibodies) in vitro.</text>
					<arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="61">
					<text>In addition, HIV-specific CD4+ T cells in viremic patients is able to proliferate in response to HIV antigens when costimulation was provided by anti-CD28 antibodies in vitro.</text>
					<arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
					<arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="61">
					<text>In addition, A0 is able to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibodies) in vitro.</text>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="62">
					<text>In addition, HD CD4+ T cells specific for HIV in viremic patients is able to proliferate in response to HIV antigens when costimulation was provided by anti-CD28 antibodies in vitro.</text>
					<arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
					<arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="62">
					<text>In addition, HD CD4+ T cells specific to HIV in viremics patients is able to proliferate in response to HIV A1 antigens (when costimulation was provided by anti-CD28 antibodies) in vitro.</text>
					<arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="63">
					<text>In addition, HIV-specific A0, CD4+T cells from viremic patients were found to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="63">
					<text>In addition, HIV-specific CD4+ T cells in viremic patients were proliferate to be proliferative in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="64">
					<text>In addition, it could be proliferate that CD4+ HIV T cells proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
					<arg n="0">CD4+ HIV T cells</arg>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="64">
					<text>In addition, HD CD4+ T cells specific for HIV in viremic patients may be observed to proliferate in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
					<arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="65">
					<text>In addition, it could be shown that CCD4+ HIV-specific cells of viremic patients proliferates in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
					<arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="65">
					<text>In addition, it can be proliferate that HD CD4+ T cells specific to HIV in viremics patients proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibodies) in vitro.</text>
					<arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="66">
					<text>In addition, HIV-specific T cells CCD4+ in viremic patients was found to proliferate in response to HIV antigens when co-stimulation was provided by anti-CD28 antibodies in vitro.</text>
					<arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
					<arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="66">
					<text>In addition, CCD4+ HIV-specific T cells of viremic patients has been found to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
					<arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="67">
					<text>In addition, HIV-specific T-cells CCD4+ in viraemic patients has been found to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
					<arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="67">
					<text>In addition, CCD4+ HIV-specific T cells of viremic patients has been found to proliferate strongly in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
					<arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="68">
					<text>In addition, HDCD4+ T cells specific to HIV in viremics patients proliferated in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
					<arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="68">
					<text>In addition, it has been proliferate that CD4+ HIV T cells proliferate in response to HIV A1 antigens (when costimulation was provided by anti-CD28 antibody) in vitro.</text>
					<arg n="0">CD4+ HIV T cells</arg>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="69">
					<text>In addition, it was observed that A0 cells (CD4+-specific HDD for HIV in viremics patients) proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="69">
					<text>In addition, HD-specific T CD4+ cells for HIV in viremic patients was observed to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
					<arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="70">
					<text>In addition, it has been shown that HIV-specific CD4+T blood cells in viremic patients proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibodies) in vitro.</text>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="70">
					<text>In addition, it has been shown that HIV-specific CD4+ T cells in viremic patients proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="71">
					<text>In addition, HIV-specific CD4+ T cells in viremic patients has been shown to be highly proliferating in response to HIV antigens when costimulation was provided by anti-CD28 antibodies in vitro.</text>
					<arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
					<arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="71">
					<text>In addition, it has been shown that HIV-specific CD4+T blood cells in viremic patients are highly proliferating in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibodies) in vitro.</text>
					<arg n="2">in vitro</arg>
				</example>
				<example src="EGRAM" no="72">
					<text>HSC may continue to proliferate in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in phase G0/ G1.</text>
					<arg n="0">HSC</arg>
					<arg n="1">through 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="72">
					<text>HSC may continue to proliferate in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">via 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="73">
					<text>HSC may continue to proliferate strongly in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">through 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="73">
					<text>HSC may continue to proliferate strongly in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">via 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="74">
					<text>HSC continued to proliferate in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">with 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="74">
					<text>HSC continued to proliferate in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">through 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="75">
					<text>HSC continued to proliferate strongly in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">with 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="75">
					<text>HSC continued to proliferate strongly in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">through 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="76">
					<text>HSC has the ability to continue to proliferate in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">with 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="76">
					<text>HSC has the ability to continue to proliferate in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">through 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="77">
					<text>HSC has the ability to continue to proliferate strongly in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">with 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="77">
					<text>HSC has the ability to continue to proliferate strongly in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">through 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="78">
					<text>HSC is likely to continue to proliferate in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">with 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="78">
					<text>HSC is likely to continue to proliferate in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">through 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="79">
					<text>HSC is likely to continue to proliferate strongly in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">with 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="79">
					<text>HSC is likely to continue to proliferate strongly in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">through 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="80">
					<text>HSC is able to continue to proliferate in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">with 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="80">
					<text>HSC is able to continue to proliferate in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">through 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="81">
					<text>HSC is able to continue to proliferate strongly in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">approximately 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and splendor</arg>
				</example>
				<example src="EGRAM" no="81">
					<text>HSC is able to continue to proliferate strongly in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">through 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="82">
					<text>It is observed that HSC continues to proliferate in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">approximately 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and splendor</arg>
				</example>
				<example src="EGRAM" no="82">
					<text>HSC is observed to continue to proliferate in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">through 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="83">
					<text>HSC is a disease that proliferate with great proliferation in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tends to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">through 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="83">
					<text>It is observed that HSC continues to proliferate strongly in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in phase G0/G1.</text>
					<arg n="0">HSC</arg>
					<arg n="1">via 8 days of G-CSF treatment</arg>
					<arg n="2">in the bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="84">
					<text>HSC may have continued to proliferate in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">approximately 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and splendor</arg>
				</example>
				<example src="EGRAM" no="84">
					<text>HSC may have continued to proliferate in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">through 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="85">
					<text>HSC may have continued to proliferate strongly in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">roughly 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and splendor</arg>
				</example>
				<example src="EGRAM" no="85">
					<text>HSC may have continued to proliferate strongly in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">through 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="86">
					<text>HSC will continue to proliferate in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in phase G0/ G1.</text>
					<arg n="0">HSC</arg>
					<arg n="1">through 8 days of G-CSF treatment</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="86">
					<text>HSC will continue to proliferate in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">with 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="87">
					<text>HSC will continue to proliferate strongly in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">via 8 days of G-CSF treatment</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="87">
					<text>HSC will continue to proliferate strongly in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
					<arg n="0">HSC</arg>
					<arg n="1">through 8 days of treatment with G-CSF</arg>
					<arg n="2">in bone marrow and spleen</arg>
				</example>
				<example src="EGRAM" no="88">
					<text>Fetal cells transplanted intrasplenicly, as our results, are able to proliferate and differentiate into mature cells that have GST expression patterns with enzymatic activities similar to those of the adult liver.</text>
				</example>
				<example src="EGRAM" no="88">
					<text>Intrasplintly transplanted fetal cells, as our results have shown, are able to proliferate and differentiate into mature cells that show a GST expression pattern with enzymatic activities similar to those of the adult liver.</text>
				</example>
				<example src="EGRAM" no="89">
					<text>intrasplens transplanted liver cells, as our results, are proliferate for proliferation and differentiation into mature cells, presenting a GST expression pattern with their respective enzymatic activities similar to the adult liver.</text>
					<arg n="0">intrasplens transplanted liver cells</arg>
				</example>
				<example src="EGRAM" no="89">
					<text>feet cells transplanted intrasplenically, as our results have shown, are observed to proliferate and differentiate into mature cells that show a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
					<arg n="0">feet cells transplanted intrasplenically</arg>
				</example>
				<example src="EGRAM" no="90">
					<text>fetal liver cells transplanted intrasplenically, as our results, proliferate and proliferated into mature cells with GST expression patterns with enzymatic activities similar to the adult liver.</text>
					<arg n="0">fetal liver cells transplanted intrasplenically</arg>
				</example>
				<example src="EGRAM" no="90">
					<text>intra-splintly transplanted fetal shapes, as our results have shown, has proliferated and differentiated into mature cells that show a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
					<arg n="0">intra-splintly transplanted fetal shapes</arg>
				</example>
				<example src="EGRAM" no="91">
					<text>fetal liver cells transplanted intrasplenically, as our results, has the ability to proliferate and differentiate into mature cells, presenting a GST expression pattern with their respective enzymatic activities similar to the adult liver.</text>
					<arg n="0">fetal liver cells transplanted intrasplenically</arg>
				</example>
				<example src="EGRAM" no="91">
					<text>A0, as our results have shown, has the ability to proliferate and differentiate into mature cells that show a GST expression pattern with enzymatic activities similar to those of the adult liver.</text>
				</example>
				<example src="EGRAM" no="92">
					<text>intrasplensally transplanted liver cells, as a result, may have proliferated and differentiated into mature cells with GST expression patterns with enzymatic activities similar to the adult liver.</text>
					<arg n="0">intrasplensally transplanted liver cells</arg>
				</example>
				<example src="EGRAM" no="92">
					<text>A0, as our results have shown, may have proliferated and differentiated into mature cells that show a GST expression pattern with enzymatic activities similar to those of the adult liver.</text>
				</example>
				<example src="EGRAM" no="93">
					<text>intra-splate transplant feet cells, as our results show, proliferate and proliferated into mature cells that have a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
					<arg n="0">intra-splate transplant feet cells</arg>
				</example>
				<example src="EGRAM" no="93">
					<text>feet cells transplanted intra-splintly, as our results have shown, proliferate and proliferated into mature cells that show a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
					<arg n="0">feet cells transplanted intra-splintly</arg>
				</example>
				<example src="EGRAM" no="94">
					<text>fetal liver cells transplanted intrasplenically, as our results, will proliferate and differentiate into mature cells with GST expression patterns with enzymatic activities similar to the adult liver.</text>
					<arg n="0">fetal liver cells transplanted intrasplenically</arg>
				</example>
				<example src="EGRAM" no="94">
					<text>A0, as our results have shown, will proliferate and differentiate into mature cells that show a GST expression pattern with enzymatic activities similar to those of the adult liver.</text>
				</example>
				<example src="EGRAM" no="95">
					<text>Our observations illustrate that the human placenta can be endowed with biochemical machinery to proliferate indefinitely along gestation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
					<arg n="0">the human placenta</arg>
					<arg n="1">along gestation</arg>
				</example>
				<example src="EGRAM" no="95">
					<text>Our results illustrate that human placenta can be equipped with a biochemical machine to proliferate definitely during pregnancy, but there are intrinsic mechanisms that effectively circumvent the extent and duration of trophoblast proliferation.</text>
					<arg n="0">human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="96">
					<text>Our observations illustrate that the human placenta can be endowed with biochemical machinery to proliferate along gestation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
					<arg n="0">the human placenta</arg>
					<arg n="1">along gestation</arg>
				</example>
				<example src="EGRAM" no="96">
					<text>Our results illustrate that human placenta may be equipped with a biochemical machine to proliferate during pregnancy, but there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
					<arg n="0">human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="97">
					<text>Our results illustrate that the human placenta was equipped with a biochemical machine to proliferate definitively during pregnancy, however, there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
					<arg n="0">the human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="97">
					<text>Our observations illustrate that the human placenta has been endowed with biochemical machinery to proliferate indefinitely along gestation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
					<arg n="0">the human placenta</arg>
					<arg n="1">along gestation</arg>
				</example>
				<example src="EGRAM" no="98">
					<text>Our results illustrate that the human placenta has been equipped with a biochemical machine to proliferate during pregnancy, but there are intrinsic mechanisms that really circumscribe the extent and duration of trophoblast proliferation.</text>
					<arg n="0">the human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="98">
					<text>Our results illustrate that the human placenta has been equipped with a biochemical machine to proliferate during pregnancy, but there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
					<arg n="0">the human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="99">
					<text>Our results illustrate that the human placenta has the ability to be equipped with a biochemical machine to proliferate definitively during pregnancy, but there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
					<arg n="0">the human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="99">
					<text>Our results illustrate that the human placenta has the ability to be equipped with a biochemical machine to proliferate definitely during pregnancy, but there are intrinsic mechanisms that actually circumscribe the extent and duration of trophoblast proliferation.</text>
					<arg n="0">the human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="100">
					<text>Our results illustrate that human placenta has the ability to be equipped with a biochemical machine to proliferate during pregnancy, but there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
					<arg n="0">human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="100">
					<text>Our results illustrate that human placenta has the ability to be equipped with a biochemical machine to proliferate during pregnancy, but there are intrinsic mechanisms that really circumscribe the extent and duration of trophoblast proliferation.</text>
					<arg n="0">human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="101">
					<text>Our results illustrate that the human placenta is able to be equipped with biochemical machines to proliferate definitely during pregnancy, however, there are intrinsic mechanisms that effectively circumvent the extent and duration of troblast proliferation.</text>
					<arg n="0">the human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="101">
					<text>Our results illustrate that the human placenta is able to be equipped with a biochemical machine to proliferate definitely during pregnancy, however, there are intrinsic mechanisms that effectively circumvent the extent and duration of trophoblast proliferation.</text>
					<arg n="0">the human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="102">
					<text>Our results illustrate that human placenta is able to be equipped with biochemical machines to proliferate pregnancy, however, there are intrinsic mechanisms that effectively circumvent the extent and duration of troblast proliferation.</text>
					<arg n="0">human placenta</arg>
					<arg n="1">pregnancy</arg>
				</example>
				<example src="EGRAM" no="102">
					<text>Our results illustrate that human placenta is able to be equipped with a biochemical machine to proliferate during pregnancy, but there are intrinsic mechanisms that really circumscribe the extent and duration of trophoblast proliferation.</text>
					<arg n="0">human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="103">
					<text>Our results illustrate that human placenta is equipped with a biochemical machine to proliferate indeterminately during pregnancy, however, there are intrinsic mechanisms that effectively circumvent the extent and duration of trophoblast proliferation.</text>
					<arg n="0">human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="103">
					<text>Our observations illustrate that the human placenta is endowed with biochemical machinery to proliferate indefinitely along gestation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
					<arg n="0">the human placenta</arg>
					<arg n="1">along gestation</arg>
				</example>
				<example src="EGRAM" no="104">
					<text>Our results illustrate that human placenta is equipped with a biochemical machine to proliferate during pregnancy, however, there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
					<arg n="0">human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="104">
					<text>Our results illustrate that human placenta is shown to be equipped with a biochemical machine to proliferate during pregnancy, however, there are intrinsic mechanisms that really circumscribe the extent and duration of trophoblast proliferation.</text>
					<arg n="0">human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="105">
					<text>Our observations illustrate that the human placenta could have been endowed with biochemical machinery to proliferate indefinitely along gestation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
					<arg n="0">the human placenta</arg>
					<arg n="1">along gestation</arg>
				</example>
				<example src="EGRAM" no="105">
					<text>Our results illustrate that human placenta may have been equipped with a biochemical machine to proliferate definitely during pregnancy, but there are intrinsic mechanisms that effectively circumvent the extent and duration of trophoblast proliferation.</text>
					<arg n="0">human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="106">
					<text>Our results illustrate that human placenta might have been equipped with a biochemical machine to proliferate during pregnancy, but there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
					<arg n="0">human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="106">
					<text>Our results illustrate that the human placenta could have been equipped with biochemical machines to proliferate through pregnancy, but there are intrinsic mechanisms that really circumscribe the extent and duration of troblast proliferation.</text>
					<arg n="0">the human placenta</arg>
					<arg n="1">through pregnancy</arg>
				</example>
				<example src="EGRAM" no="107">
					<text>Our results illustrate that human placenta was equipped with a biochemical machine to proliferate indeterminately during pregnancy, however, there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
					<arg n="0">human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="107">
					<text>Our observations illustrate that the human placenta was endowed with biochemical machinery to proliferate indefinitely along gestation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
					<arg n="0">the human placenta</arg>
					<arg n="1">along gestation</arg>
				</example>
				<example src="EGRAM" no="108">
					<text>Our observations illustrate that the human placenta was endowed with biochemical machinery to proliferate along gestation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
					<arg n="0">the human placenta</arg>
					<arg n="1">along gestation</arg>
				</example>
				<example src="EGRAM" no="108">
					<text>Our results illustrate that human placenta was equipped with a biochemical machine to proliferate during pregnancy, however, there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
					<arg n="0">human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="109">
					<text>Our results illustrate that human placenta will be equipped with a biochemical machine to proliferate definitely during pregnancy, however, there are intrinsic mechanisms that effectively circumvent the extent and duration of trophoblast proliferation.</text>
					<arg n="0">human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="109">
					<text>Our observations illustrate that the human placenta will be endowed with biochemical machinery to proliferate indefinitely along gestation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
					<arg n="0">the human placenta</arg>
					<arg n="1">along gestation</arg>
				</example>
				<example src="EGRAM" no="110">
					<text>Our results illustrate that human placenta will be equipped with a biochemical machine to proliferate during pregnancy, but there are intrinsic mechanisms that really circumscribe the extent and duration of trophoblast proliferation.</text>
					<arg n="0">human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="110">
					<text>Our results illustrate that human placenta will be equipped with a biochemical machine to proliferate during pregnancy, but there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
					<arg n="0">human placenta</arg>
					<arg n="1">during pregnancy</arg>
				</example>
				<example src="EGRAM" no="111">
					<text>T A0 cells are able to proliferate the undefined proliferation capacity after the introduction of Stat5a wild body estuation (picture 6B).</text>
					<arg n="1">after the introduction of Stat5a wild body estuation</arg>
				</example>
				<example src="EGRAM" no="111">
					<text>A0 T cells are able to recover the ability to proliferate indefinitely after the introduction of Stat5a wild body stulation (Figure 6B).</text>
					<arg n="1">after the introduction of Stat5a wild body stulation</arg>
				</example>
				<example src="EGRAM" no="112">
					<text>stat5ab-/-peripheral T cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
					<arg n="0">stat5ab-/-peripheral T cells</arg>
				</example>
				<example src="EGRAM" no="112">
					<text>T cells Stat5ab/-peripheral are able to recover the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
					<arg n="0">Stat5ab/-peripheral</arg>
					<arg n="1">after the introduction of Stat5a stulation</arg>
				</example>
				<example src="EGRAM" no="113">
					<text>It is proliferate that stat5ab/-peripheral T cells regains the undefined proliferation capability after the introduction of the full wild-length state5a (image 6B).</text>
					<arg n="0">stat5ab/-peripheral T cells</arg>
					<arg n="1">after the introduction of the full wild-length state5a</arg>
				</example>
				<example src="EGRAM" no="113">
					<text>It is observed that Stat5ab-/-peripheral T cells regains the ability to proliferate indefinitely after the introduction of wild body stat5a (Figure 6B).</text>
					<arg n="0">Stat5ab-/-peripheral T cells</arg>
					<arg n="1">after the introduction of wild body stat5a</arg>
				</example>
				<example src="EGRAM" no="114">
					<text>It is observed that Stat5ab-/-peripheral T cells regains the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
					<arg n="0">Stat5ab-/-peripheral T cells</arg>
					<arg n="1">after the introduction of Stat5a stulation</arg>
				</example>
				<example src="EGRAM" no="114">
					<text>stat5ab-/-peripheral T cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
					<arg n="0">stat5ab-/-peripheral T cells</arg>
				</example>
				<example src="EGRAM" no="115">
					<text>stat5ab-/-peripheral T cells may proliferate the undefined proliferation capacity after the introduction of the full wild-length Stat5a (picture 6B).</text>
					<arg n="0">stat5ab-/-peripheral T cells</arg>
					<arg n="1">after the introduction of the full wild-length Stat5a</arg>
				</example>
				<example src="EGRAM" no="115">
					<text>Stat5ab-/-peripheral T cells can regain the ability to proliferate indefinitely after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
					<arg n="0">Stat5ab-/-peripheral T cells</arg>
					<arg n="1">after the introduction of Stat5a of full-length wild type</arg>
				</example>
				<example src="EGRAM" no="116">
					<text>stat5ab-/-peripheral T cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
					<arg n="0">stat5ab-/-peripheral T cells</arg>
				</example>
				<example src="EGRAM" no="116">
					<text>Stat5ab-/-peripheral T cells can regain the ability to proliferate after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
					<arg n="0">Stat5ab-/-peripheral T cells</arg>
					<arg n="1">after the introduction of Stat5a of full-length wild type</arg>
				</example>
				<example src="EGRAM" no="117">
					<text>stat5ab-/-peripheral T cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
					<arg n="0">stat5ab-/-peripheral T cells</arg>
				</example>
				<example src="EGRAM" no="117">
					<text>Stat5ab-/-peripheral T cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
					<arg n="0">Stat5ab-/-peripheral T cells</arg>
				</example>
				<example src="EGRAM" no="118">
					<text>stat5ab/-peripheral T cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
					<arg n="0">stat5ab/-peripheral T cells</arg>
				</example>
				<example src="EGRAM" no="118">
					<text>Stat5ab-/-peripheral T cells has regained the ability to proliferate after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
					<arg n="0">Stat5ab-/-peripheral T cells</arg>
					<arg n="1">after the introduction of Stat5a of full-length wild type</arg>
				</example>
				<example src="EGRAM" no="119">
					<text>stat5ab/peripheral T cells is likely to proliferate the undefined proliferation capacity after the introduction of the full wild-length Stat5a (picture 6B).</text>
					<arg n="0">stat5ab/peripheral T cells</arg>
					<arg n="1">after the introduction of the full wild-length Stat5a</arg>
				</example>
				<example src="EGRAM" no="119">
					<text>Stat5ab-/-peripheral T cells has the probability of recovering the ability to proliferate indefinitely after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
					<arg n="0">Stat5ab-/-peripheral T cells</arg>
					<arg n="1">after the introduction of Stat5a of full-length wild type</arg>
				</example>
				<example src="EGRAM" no="120">
					<text>stat5ab/-peripheral T cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
					<arg n="0">stat5ab/-peripheral T cells</arg>
				</example>
				<example src="EGRAM" no="120">
					<text>Stat5ab-/-peripheral T cells has the probability of recovering the ability to proliferate after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
					<arg n="0">Stat5ab-/-peripheral T cells</arg>
					<arg n="1">after the introduction of Stat5a of full-length wild type</arg>
				</example>
				<example src="EGRAM" no="121">
					<text>stat5ab-/-peripheral T cells may proliferate recovered the undefined proliferation capacity after the introduction of the full wild-length Stat5a type (picture 6B).</text>
					<arg n="0">stat5ab-/-peripheral T cells</arg>
					<arg n="1">after the introduction of the full wild-length Stat5a type</arg>
				</example>
				<example src="EGRAM" no="121">
					<text>Stat5ab-/-peripheral T cells may have regained the ability to proliferate indefinitely after the introduction of the full-length wild type Stat5a (Figure 6B).</text>
					<arg n="0">Stat5ab-/-peripheral T cells</arg>
					<arg n="1">after the introduction of the full-length wild type Stat5a</arg>
				</example>
				<example src="EGRAM" no="122">
					<text>stat5ab/peripheral T cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
					<arg n="0">stat5ab/peripheral T cells</arg>
				</example>
				<example src="EGRAM" no="122">
					<text>Stat5ab-/-peripheral T cells may have regained the ability to proliferate after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
					<arg n="0">Stat5ab-/-peripheral T cells</arg>
					<arg n="1">after the introduction of Stat5a of full-length wild type</arg>
				</example>
				<example src="EGRAM" no="123">
					<text>stat5ab-/-peripheral T cells proliferate the undefined proliferation capacity after the introduction of the full wild-length Stat5a type (picture 6B).</text>
					<arg n="0">stat5ab-/-peripheral T cells</arg>
					<arg n="1">after the introduction of the full wild-length Stat5a type</arg>
				</example>
				<example src="EGRAM" no="123">
					<text>Stat5ab-/-peripheral T cells regained the ability to proliferate indefinitely after the introduction of the full-length wild type Stat5a (Figure 6B).</text>
					<arg n="0">Stat5ab-/-peripheral T cells</arg>
					<arg n="1">after the introduction of the full-length wild type Stat5a</arg>
				</example>
				<example src="EGRAM" no="124">
					<text>stat5ab/peripheral T cells recovered the ability to proliferate after the introduction of the completely length wild-type Stat5a (picture 6B).</text>
					<arg n="0">stat5ab/peripheral T cells</arg>
					<arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
				</example>
				<example src="EGRAM" no="124">
					<text>The Stat5ab/-peripheral T cells regained the ability to proliferate the after the introduction of the Stat5a complete-length wild type (Figure 6B).</text>
					<arg n="0">Stat5ab/-peripheral T cells</arg>
					<arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
				</example>
				<example src="EGRAM" no="125">
					<text>stat5ab/peripheral T cells will proliferate the undefined proliferation capability after the introduction of the full wild-length state5a (image 6B).</text>
					<arg n="0">stat5ab/peripheral T cells</arg>
					<arg n="1">after the introduction of the full wild-length state5a</arg>
				</example>
				<example src="EGRAM" no="125">
					<text>Stat5ab-/-peripheral T cells will regain the ability to proliferate indefinitely after the introduction of the Stat5a type of complete wild size (Figure 6B).</text>
					<arg n="0">Stat5ab-/-peripheral T cells</arg>
					<arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
				</example>
				<example src="EGRAM" no="126">
					<text>stat5ab/peripheral T cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
					<arg n="0">stat5ab/peripheral T cells</arg>
				</example>
				<example src="EGRAM" no="126">
					<text>Stat5ab-/-peripheral T cells will regain the ability to proliferate after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
					<arg n="0">Stat5ab-/-peripheral T cells</arg>
					<arg n="1">after the introduction of Stat5a of full-length wild type</arg>
				</example>
				<example src="EGRAM" no="127">
					<text>The ability of A0 cells (BT) to proliferate in vivo was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="127">
					<text>The ability of EBD cells to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">EBD cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="128">
					<text>The ability of A0 cells (BT) to proliferate strongly in vivo was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="128">
					<text>The ability of EBD cells to strongly proliferate in vivo was proliferate by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">EBD cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="129">
					<text>The ability of A0 cells (BT) to proliferate in vivo was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="129">
					<text>The ability of A0 cells (EBD) to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="130">
					<text>The ability of A0 cells (BT) to proliferate strongly in vivo was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="130">
					<text>The ability of EBD cells to proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">EBD cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="131">
					<text>The ability of BI cells to proliferated in vivo was examined by injection of 3? 106 LVTE into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">BI cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="131">
					<text>The ability of EBD cells that have proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">EBD cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="132">
					<text>The ability of A0 cells (BT) to proliferated strongly in vivo was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="132">
					<text>The ability of EBD cells that have strongly proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">EBD cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="133">
					<text>The ability of A0 cells (BT) to proliferate in vivo was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="133">
					<text>The ability of EBD cells to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">EBD cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="134">
					<text>The ability of A0 cells (BT) to have the ability to proliferate strongly in vivo was examined by injection of 3? 106 CVC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="134">
					<text>The ability of EBD cells that have the ability to proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">EBD cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="135">
					<text>The TBI cells proliferating A2 capacity (in vivo) was proliferating by injection of 3? 106 CVC cells in the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">TBI cells</arg>
				</example>
				<example src="EGRAM" no="135">
					<text>The capacity of EBD cells proliferating in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">EBD cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="136">
					<text>The ability of EBD cells that can proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">EBD cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="136">
					<text>The BT cells capacity that can proliferate in vivo was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
					<arg n="0">BT cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="137">
					<text>The ability of BT cells that can proliferate strongly in vivo was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">BT cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="137">
					<text>The ability of EBD cells that can strongly proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">EBD cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="138">
					<text>The BT cells capacity that proliferated in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">BT cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="138">
					<text>The ability of EBD cells that have proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">EBD cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="139">
					<text>The A0 capacity (BT cells) that showed a great A2 proliferation (in vivo) was proliferated by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
				</example>
				<example src="EGRAM" no="139">
					<text>The ability of EBD cells that have strongly proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">EBD cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="140">
					<text>The ability of A0 cells (EBD) that have the ability to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="140">
					<text>The ability to proliferate in vivo was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="141">
					<text>The ability of A0 cells (EBD) that have the ability to proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="141">
					<text>The ability to proliferate strongly in vivo was examined by injection of 3? 106 CVC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="142">
					<text>The ability of EBD cells that is capable of proliferating in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">EBD cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="142">
					<text>The ability to proliferate in vivo has been examined by injection of 3? 106 LVTE cells into the veil muscle of 3 immunocompromised mice.</text>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="143">
					<text>The ability of EBD cells that is capable of strongly proliferating in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">EBD cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="143">
					<text>The ability of BT cells that is able to proliferate strongly in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">BT cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="144">
					<text>The ability of A0 cells (EBD) proliferating to in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="144">
					<text>The ability to proliferate in vivo was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="145">
					<text>The ability of BT cells that was observed to proliferate strongly in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">BT cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="145">
					<text>The ability of A0 cells (BT) observed to proliferate strongly in vivo was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="146">
					<text>The ability of EBD cells that may have proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">EBD cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="146">
					<text>The A0 capacity (BT cells) that may have proliferated in vivo was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="147">
					<text>The capacity of BT cells that may have proliferated strongly in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">BT cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="147">
					<text>The ability of EBD cells that may have strongly proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">EBD cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="148">
					<text>The ability of EBD cells that can proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">EBD cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="148">
					<text>The BT cells capacity that can proliferate in vivo was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
					<arg n="0">BT cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="149">
					<text>The ability of BT cells that can proliferate strongly in vivo was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">BT cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="149">
					<text>The ability of EBD cells that can strongly proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">EBD cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="150">
					<text>The ability of EBD cells to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">EBD cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="150">
					<text>The ability to proliferate in vivo was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="151">
					<text>The BT cells capacity that will proliferate strongly in vivo has been examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">BT cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="151">
					<text>The ability of EBD cells that proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
					<arg n="0">EBD cells</arg>
					<arg n="2">in vivo</arg>
				</example>
				<example src="EGRAM" no="152">
					<text>These results show that fetal liver cells transplanted intrasplenically is able to proliferate and differentiate into mature cells with GST expression patterns with enzymatic activities similar to the adult liver.</text>
					<arg n="0">fetal liver cells transplanted intrasplenically</arg>
				</example>
				<example src="EGRAM" no="152">
					<text>These results show that intraspontically transplanted fetal cells are able to proliferate and differentiate into mature cells that show a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
					<arg n="0">intraspontically transplanted fetal cells</arg>
				</example>
				<example src="EGRAM" no="153">
					<text>These results show that transplant feet cells intrasplenomegaly proliferates and proliferate into mature cells that have GST expression patterns with enzymatic activities similar to those of the adult liver.</text>
					<arg n="0">transplant feet cells intrasplenomegaly</arg>
				</example>
				<example src="EGRAM" no="153">
					<text>These results show that feet cells transplanted intrasplentically proliferate and proliferate into mature cells that show a GST expression pattern with enzymatic activities similar to those of the adult liver.</text>
					<arg n="0">feet cells transplanted intrasplentically</arg>
				</example>
				<example src="EGRAM" no="154">
					<text>These results show that A0 has proliferated and differentiated in mature cells showing a TGS expression pattern with respective enzymatic activities similar to the adult liver.</text>
				</example>
				<example src="EGRAM" no="154">
					<text>These results show that A0 has proliferated and differentiated into mature cells showing a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
				</example>
				<example src="EGRAM" no="155">
					<text>These results show that fetal liver cells transplanted intrasplenically has the ability to proliferate and differentiate into mature cells with GST expression patterns with enzymatic activities similar to the adult liver.</text>
					<arg n="0">fetal liver cells transplanted intrasplenically</arg>
				</example>
				<example src="EGRAM" no="155">
					<text>These results show that intraspontically transplanted fetal cells have the ability to proliferate and differentiate into mature cells that show a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
					<arg n="0">intraspontically transplanted fetal cells</arg>
				</example>
				<example src="EGRAM" no="156">
					<text>These results show that intrasplens transplanted liver cells may have proliferated and differentiated into mature cells with GST expression patterns with enzymatic activities similar to the adult liver.</text>
					<arg n="0">intrasplens transplanted liver cells</arg>
				</example>
				<example src="EGRAM" no="156">
					<text>These results show that intrasplensally transplanted fetal cells may have proliferated and differentiated into mature cells that show a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
					<arg n="0">intrasplensally transplanted fetal cells</arg>
				</example>
				<example src="EGRAM" no="157">
					<text>These results show that intra-splenic transplant fetal cells progresses and proliferated into mature cells that have GST expression patterns with respective enzymatic activities similar to the adult liver.</text>
					<arg n="0">intra-splenic transplant fetal cells</arg>
				</example>
				<example src="EGRAM" no="157">
					<text>These results show that intrasplintly transplanted fetal cells proliferates and proliferated into mature cells that show a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
					<arg n="0">intrasplintly transplanted fetal cells</arg>
				</example>
				<example src="EGRAM" no="158">
					<text>These results show that fetal liver cells transplanted intrasplenically will proliferate and differentiate into mature cells with GST expression patterns with enzymatic activities similar to the adult liver.</text>
					<arg n="0">fetal liver cells transplanted intrasplenically</arg>
				</example>
				<example src="EGRAM" no="158">
					<text>These results show that intrasponntically transplanted fetal cells will proliferate and differentiate into mature cells that show a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
					<arg n="0">intrasponntically transplanted fetal cells</arg>
				</example>
				<example src="EGRAM" no="159">
					<text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
					<arg n="0">endothelial cells</arg>
				</example>
				<example src="EGRAM" no="159">
					<text>Treatment of endothelial cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate when exposed to FGF2.</text>
					<arg n="0">endothelial cells</arg>
					<arg n="1">when exposed to FGF2</arg>
				</example>
				<example src="EGRAM" no="160">
					<text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
					<arg n="0">endothelial cells</arg>
				</example>
				<example src="EGRAM" no="160">
					<text>Treatment of endothelial cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate when exposed to FGF2.</text>
					<arg n="0">endothelial cells</arg>
					<arg n="1">when exposed to FGF2</arg>
				</example>
				<example src="EGRAM" no="161">
					<text>The treatment of endothelial cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
					<arg n="0">endothelial cells</arg>
				</example>
				<example src="EGRAM" no="161">
					<text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
					<arg n="0">endothelial cells</arg>
				</example>
				<example src="EGRAM" no="162">
					<text>The treatment of endothelial cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate when exposed to FGF2.</text>
					<arg n="0">endothelial cells</arg>
					<arg n="1">when exposed to FGF2</arg>
				</example>
				<example src="EGRAM" no="162">
					<text>Treatment of endothelial cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
					<arg n="0">endothelial cells</arg>
				</example>
				<example src="EGRAM" no="163">
					<text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
					<arg n="0">endothelial cells</arg>
				</example>
				<example src="EGRAM" no="163">
					<text>Treatment of endothelial cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate when exposed to FGF2.</text>
					<arg n="0">endothelial cells</arg>
					<arg n="1">when exposed to FGF2</arg>
				</example>
				<example src="EGRAM" no="164">
					<text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
					<arg n="0">endothelial cells</arg>
				</example>
				<example src="EGRAM" no="164">
					<text>Treatment of endothelial cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate when exposed to FGF2.</text>
					<arg n="0">endothelial cells</arg>
					<arg n="1">when exposed to FGF2</arg>
				</example>
				<example src="EGRAM" no="165">
					<text>Treatment of endothelial cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
					<arg n="0">endothelial cells</arg>
				</example>
				<example src="EGRAM" no="165">
					<text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
					<arg n="0">endothelial cells</arg>
				</example>
				<example src="EGRAM" no="166">
					<text>Treatment of endothelial cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate when exposed to FGF2.</text>
					<arg n="0">endothelial cells</arg>
					<arg n="1">when exposed to FGF2</arg>
				</example>
				<example src="EGRAM" no="166">
					<text>Treatment of endothelial cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
					<arg n="0">endothelial cells</arg>
				</example>
				<example src="EGRAM" no="167">
					<text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
					<arg n="0">endothelial cells</arg>
				</example>
				<example src="EGRAM" no="167">
					<text>The treatment of endothelial cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate when exposed to FGF2.</text>
					<arg n="0">endothelial cells</arg>
					<arg n="1">when exposed to FGF2</arg>
				</example>
				<example src="EGRAM" no="168">
					<text>Treatment of endothelial cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
					<arg n="0">endothelial cells</arg>
				</example>
				<example src="EGRAM" no="168">
					<text>The treatment of endothelial cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate when exposed to FGF2.</text>
					<arg n="0">endothelial cells</arg>
					<arg n="1">when exposed to FGF2</arg>
				</example>
				<example src="EGRAM" no="169">
					<text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
					<arg n="0">endothelial cells</arg>
				</example>
				<example src="EGRAM" no="169">
					<text>Treatment of endothelial cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate when exposed to FGF2.</text>
					<arg n="0">endothelial cells</arg>
					<arg n="1">when exposed to FGF2</arg>
				</example>
				<example src="EGRAM" no="170">
					<text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl, significant impairment of its proliferation capacity A1 (proliferate to FGF2</text>
					<arg n="0">endothelial cells</arg>
				</example>
				<example src="EGRAM" no="170">
					<text>The treatment of endothelial cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate when exposed to FGF2.</text>
					<arg n="0">endothelial cells</arg>
					<arg n="1">when exposed to FGF2</arg>
				</example>
				<example src="EGRAM" no="171">
					<text>Treatment of endothelial cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate when exposed to FGF2.</text>
					<arg n="0">endothelial cells</arg>
					<arg n="1">when exposed to FGF2</arg>
				</example>
				<example src="EGRAM" no="171">
					<text>Treatment of endothelial cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
					<arg n="0">endothelial cells</arg>
				</example>
				<example src="EGRAM" no="172">
					<text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
					<arg n="0">endothelial cells</arg>
				</example>
				<example src="EGRAM" no="172">
					<text>Treatment of endothelial cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate when exposed to FGF2.</text>
					<arg n="0">endothelial cells</arg>
					<arg n="1">when exposed to FGF2</arg>
				</example>
			</roleset>
        </predicate>
    </framesest>
</PASBIO>